A review of genetic polymorphisms and prostate cancer risk

Annals of Epidemiology

Volumn 12, Issue 3, 2002, Pages 182-196

  Coughlin, Steven S ^a   Hall, Ingrid J ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Genetics; Polymorphisms; Prostate Cancer; Prostate neoplasms

Indexed keywords

ACYLTRANSFERASE; ANDROGEN RECEPTOR; CYTOCHROME P450 ISOENZYME; GLUTATHIONE TRANSFERASE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; VITAMIN D RECEPTOR;

ALLELE; ARTICLE; CANCER RISK; DATA BASE; DISEASE ASSOCIATION; GENE; GENETIC POLYMORPHISM; HUMAN; MALE; MEDICAL LITERATURE; MEDLINE; MOLECULAR GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EPIDEMIOLOGY, MOLECULAR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE (GENETICS); MALE; MICROSATELLITE REPEATS; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, CALCITRIOL; RISK FACTORS;

EID: 0036191218     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-2797(01)00310-6     Document Type: Article

References (89)

1. Family history and the risk of prostate cancer
2. Mendelian inheritance of familial prostate cancer
3. Family history of prostate cancer; a multi-center case-control study in Canada
4. Familial prostate cancer in Sweden; a nationwide register cohort study
5. Genetic epidemiology of prostate cancer in the Utah Mormon genealogy
6. Gronberg H, Xu J, Isaacs SD, et al.; Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search
7. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43
8. et.al.; Evidence for a prostate cancer susceptibility locus on the X chromosome
9. Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer
10. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer
11. A 6-Mb high-resolution physical and transcription map encompassing the hereditary prostate cancer 1 (HPC1) region
12. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus
13. In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer
14. Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees
15. Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group
16. Prostate cancer potentially linked to the HPC1 gene
17. Prostate cancer potentially linked to the HPC1 gene
18. Genetic variation of 3β-hydroxysteroid dehydrogenase type II in three racial/ethnic groups; implications for prostate cancer risk
19. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
20. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles
21. Androgen metabolism and prostate cancer; establishing a model of genetic susceptibility
22. Molecular genetics and epidemiology of prostate carcinoma
23. 5-α- reductase inhibition and prostate cancer prevention
24. Genetic variability of the human SRD5A2 gene; implications for prostate cancer risk
25. The emerging importance of genetics in epidemiologic research. II. Issues in study design and gene mapping
26. Genetic and environmental factors in prostate cancer genesis; identifying high-risk cohorts
27. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
28. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer
29. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor
30. Re. Prostate cancer and the androgen receptor
31. The androgen receptor gene GGN microsatellite and prostate cancer risk
32. Polymorphic repeats in the androgen receptor gene; molecular markers of prostate cancer risk
33. Polymorphic CAG and GGN repeat lengths in the AR gene and prostate cancer risk; a population-based case-control study in China
34. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
35. Links between genetic and environmental factors and prostate cancer risk
36. The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer
37. Androgen receptor polymorphisms; Association with prostate cancer risk, relapse and overall survival
38. CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population
39. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene
40. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males
41. Unusual length polymorphism in human steroid 5α-reductase type 2 gene (SRD5A2)
42. A polymorphism of the 5α-reductase gene and its association with prostate cancer; a case-control analysis
43. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase
44. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
45. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer
46. Association of SRD5A2 genotype and pathological characteristics of prostate tumors
47. Identification of a polymorphism in the ARE 1 region of the PSA promoter
48. Susceptibility to prostate cancer; Interaction between genotypes at the androgen receptor and prostate-specific antigen loci
49. Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer
50. Vitamin D receptor polymorphisms and lethal prostate cancer
51. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups; implications for association studies
52. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians
53. Vitamin D and prostate cancer; a prediagnostic study with stored sera
54. Prostate cancer and prediagnostic levels of serum vitamin D metabolites
55. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer
56. Association of prostate cancer with vitamin D receptor gene polymorphism
57. Contribution of trans-acting factor alleles to normal physiological variablility; vitamin D receptor gene polymorphisms and circulating osteocalcin
58. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans
59. Vitamin D receptor gene polymorphism in Japanese patients with prostate cancer
60. Vitamin D receptor polymorphisms and prostate cancer
61. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population
62. Vitamin D receptor polymorphisms as markers in prostate cancer
63. Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan
64. Metabolic polymorphisms and cancer susceptibility
65. Genetic metabolic polymorphisms and the risk of cancer; a review of the literature
66. Inherited susceptibility
67. Expression in human prostate of drug- and carcinogen-metabolizing enzymes; association with prostate cancer risk
68. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women
69. Functional significance of different human CYP1A1 genotypes
70. Debrisoquine hydroxylase (CYP2D6) and prostate cancer
71. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility
72. Polymorphisms in NAT2, CYP2D6, CYP2C19, and GSTP1 and their association with prostate cancer
73. A polymorphism in the CYP17 gene is associated with prostate cancer risk
74. Prostate cancer associated with CYP17 genotype
75. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect
76. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
77. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients
78. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
79. N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development
80. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility
81. Glutathione S-transferase-μ (GSTM1) and -θ (GSTT1) genotypes in the etiology of prostate cancer
82. Glutathione S-transferases as risk factors in prostate cancer
83. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer
84. Genetic epidemiology of prostate cancer
85. Epidemiology of prostate cancer
86. The uncoupling of race and cancer genetics
87. Why genes don't count (for racial differences in health)
88. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions